Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2018 | RADIUS results: midostaurin reduces relapse after ASCT in FLT3-ITD AML

Richard Thomas Maziarz • 24 Jan 2019
ASH 2018
Acute Myeloid Leukemia Leukemia Midostaurin
RADIUS-X

Richard Thomas Maziarz, MD, of the Knight Cancer Institute, Oregon Health & Science University, Portland, OR, discusses the Phase II randomized, open-label RADIUS-X trial (NCT01883362) investigating whether the addition of midostaurin after ASCT in FLT3-ITD-mutated acute myeloid leukemia (AML) could decrease the risk of relapse. Prof. Maziarz presents the promising results of this study, which met both its primary and secondary endpoints. This interview took place at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Richard Thomas Maziarz

CAR-T gives sustained disease control in R/R adult DLBCL: updated JULIET analysis
4:27
CAR-T gives sustained disease control in R/R adult DLBCL: updated JULIET analysis
Richard Thomas Maziarz • 24 Jan 2019
Updated JULIET results for tisagenlecleucel in DLBCL
5:51
Updated JULIET results for tisagenlecleucel in DLBCL
Richard Thomas Maziarz • 1 Dec 2018

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals